A minimally invasive, blood-based assay to predict and detect response to immune-checkpoint inhibitors (ICIs) would be of significant importance.1H MRS of plasma samples provides a robust reproducible assay that require minimal sample preparation, and convenience of sample storage. Here we evaluated changes in plasma metabolites of clear cell renal cell carcinoma (ccRCC) patients receiving ICIs using 1H MRS. We identified a significant increase of acetate, formate, glutamine, glycine, myoinositol, and lactate following ICI that may reflect response.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: